The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Genentech, a member of the Roche Group, announced that the phase II/III SKYSCRAPER-06 study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 [95% CI: 1.02,1.57] and overall survival at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. 
Clinical Roundup

Datopotamab deruxtecan did not reach statistical significance for OS in metastatic or advanced nonsquamous NSCLC in phase III trial

Topline overall survival results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account